RAP july, page-2

I saw many people were trying to make unnecessary public panic in other threads. The purpose is simple, they want to accumulate these shares at low price.
There are several factors that ResApp would not fail in the long term:
1.) Competitive advantage. There might be many telehealth service providers in the market, non of them have accurate diagnostic device to check severe respiratory disease. In order words, ResApp is specialised in the area. Moreover, it has an existing US telehealth partner which has 10 of million customers. Just like the takeover of instagram by facebook, it is easy to understand the potential of ResApp. Okay, if the accuracy is problematic, it will still be a headache. But so far, ResApp has never disappointed us. All the clinical result are excellent, plus, the system it is using can carry out self learning. Just a matter of time, its accuracy will improve. So some people also argue about the potential entrant into the market. But does a new entrant has similar research time to start up another system that perform the same function like ResApp? I doubt. First, ResApp was developed by UniQ 5 years ago. And after ResApp gets US trial done, it will apply for more patent, it will be exclusive. Even if there is a competition, based on the statistics of the growing telehealth market a good sales is still there.
2. US Clinical trial. The pre-submission of FDA approval meeting has already highlighted the agreement to conduct US Trial. Now, American or Australian, we are still human beings. You reckon the result will be different from the one completed in WA? Okay, I can’t control what you think. As mentioned before, the self learning ability will improve overtime. I have no idea how accurate will US trial end up be, but I expect it would not be worse than the result achieved before.
3. FDA approval. You are very right than this is the most crucial part. Big uncertainty is in there. Keating said it will take up to 180 days to get approval. Is he too optimistic? Nobody knows, but without FDA, is it the end of ResApp? I say no. How about WHO and the US partner? One is willing to invest money to reduce OECD people from suffering. Please note that, they invest to reduce their cost to cure this highly contagious disease. I see how compulsory it is for them to invest in this. While the US partner (or partners), they need to improve their devices in remote diagnosis in disease varities. I see a compulsory in there too. In the past, search engine could not intelligently display related keywords. So you must know what you want and type the exactly precise keywords. Since google bought the tech to link keyword to a database and outline all related sources, searching experience improved. In this case, I see same thing. Without FDA approval, Telehealth existing players still need new tech to upgrade their products and to maintain market share. ResApp is exclusively specialised in respiratory diseases, I see good prospect it will intergrate into some major telehealth products.
4. Not sure how big potential this ResApp tech is going to be in Australia alone. I would not neglect this but I need to DMOR.
I only express my own opinion. I can be wrong even I am so confident. I am a long-term holder.
My investment principal is: Hold your favourite stock for as long as you can. I believe most short term traders perform inferior than passive investors. Lastly, if you are on margin lending or something, you can ignore me. It’S getting hard to predict how much ResApp will be shaked off. Common-sense-wise, all good stocks recover from financial crisis. It’S totally Up to you to judge what ResApp is.